Filtered By:
Condition: Hypertension
Management: Centers for Disease Control and Prevention (CDC)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 63 results found since Jan 2013.
Stroke Down to Fifth-Leading Killer in U.S. -- Here's What the Statistical Change Really Means
In the 1970s, Joseph Broderick was a resident at the Mayo Clinic in need of a focus for his fellowship. He decided to give stroke research a try.
Part of the lure was all the unanswered questions, like: Who is most likely to have a stroke? Why do they have it when others seemingly like them don't? Is stroke getting more or less common? What can be done to prevent it?
Another part of the lure was a landmark study on the frequency of stroke being done in the hospital's hometown of Rochester, Minnesota. Being part of it meant working for one of the nation's leading stroke researchers at the time, Jack Whisnant.
By the mid-...
Source: Healthy Living - The Huffington Post - January 12, 2015 Category: Consumer Health News Source Type: news
How People With Diabetes Can Lower Stroke Risk
After spending nearly two decades trying to manage her Type 2 diabetes, Agnes Czuchlewski landed in the emergency room in 2015, with news that she’d just experienced a heart attack. She also learned that she had metabolic syndrome, a cluster of conditions that includes diabetes but also brings higher risk of heart disease and stroke.
“Because I needed to lose quite a bit of weight when I was first diagnosed, I was focused on the number I saw on the scale, and then on my blood-sugar numbers,” recalls Czuchlewski, 68, who lives in New York City. “I didn’t realize other numbers came into play, li...
Source: TIME: Health - November 10, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease healthscienceclimate Source Type: news
The Racial Gap in U.S. Stroke Deaths Got Worse During the Pandemic
NEW YORK — The longstanding racial gap in U.S. stroke death rates widened dramatically during the COVID-19 pandemic, government researchers said Thursday.
Stroke death rates increased for both Black and white adults in 2020 and 2021, according to the Centers for Disease Control and Prevention study. But the difference between the two groups grew about 22%, compared with the five years before the pandemic.
“Any health inequity that existed before seems to have been made larger during the pandemic,” said Dr. Bart Demaerschalk, a stroke researcher at the Mayo Clinic in Phoenix who was not involved in the new...
Source: TIME: Health - April 20, 2023 Category: Consumer Health News Authors: Mike Stobbe/AP Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Depression Could Double Stroke Risk In People Over 50
Published: May 13, 2015 04:35pm ET by LiveScience.
People who have depression for a long time may be at increased risk for stroke, a new study suggests.
Researchers found that adults ages 50 and older who had symptoms of depression that lasted more than two years were twice as likely to have a stroke in the following two years, compared with men and women of similar age with no signs of depression.
"The exact pathway through which depressive symptoms may lead to stroke remains unclear, and is an important area for future research," said study lead author Paola Gilsanz, a postdoctoral fellow at the Harvard T.H. Cha...
Source: Science - The Huffington Post - May 14, 2015 Category: Science Source Type: news
Johnson & Johnson Launches Heartline ™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The study is designed to explore if the Heartline™ Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline™ Study, individuals must be age 65 or older...
Source: Johnson and Johnson - February 25, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Americans Are Still Eating Too Much Salt
According to a new report from the Centers for Disease Control and Prevention (CDC), Americans are still eating too much salt. The CDC says that 9 in 10 Americans, or 90 percent, consume more sodium than the recommended amount. In the Western diet, most of the sodium we consume comes from the salt. This news is alarming because as everyone should know by now, too much salt in our diets raises our risk for heart disease and leads to potentially life-threatening conditions including high blood pressure, heart attack and stroke. The report says that more than 90 percent of children and 89 percent of adults in the United State...
Source: Healthy Living - The Huffington Post - January 12, 2016 Category: Consumer Health News Source Type: news
What to Know if Your Doctor Put You on Statins to Lower Cholesterol
High cholesterol is a prime example of having too much of a good thing. Our bodies naturally make this substance in the liver and then transport it throughout the body for multiple functions, including hormone regulation, cell tissue regeneration, and vitamin absorption. When the system is working well, cholesterol can boost overall health. But when a certain type called low-density lipoprotein—LDL, sometimes dubbed the “bad” kind—is overproduced, not only does it block the “good” kind called high-density lipoprotein (HDL), but it can also begin to accumulate in the arteries and form thi...
Source: TIME: Health - January 25, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
Is Your Heart Older Than You? Maybe, Says New Report
NEW YORK (AP) — Your heart might be older than you are.
A new government report suggests age is just a number — and perhaps not a very telling one when it comes to your risk of heart attack or stroke.
The Centers for Disease Control and Prevention report takes a new approach to try to spur more Americans to take steps to prevent cardiovascular disease.
CDC scientists estimated the average “heart age” of men and women in every state, based on risk factors like high blood pressure, obesity, and whether they smoke or have diabetes. Then it compared the numbers to average actual ages.
AVERAGE PREDICTED HEART AG...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 2, 2015 Category: Consumer Health News Authors: miketoole Tags: Health Local News CDC Framingham Source Type: news
Self-reported hypertension and use of antihypertensive medication among adults - United States, 2005-2009.
Abstract
Hypertension affects one third of adults in the United States and is a major risk factor for heart disease and stroke. A previous report found differences in the prevalence of hypertension among racial/ethnic populations in the United States; blacks had a higher prevalence of hypertension, and Hispanics had the lowest use of antihypertensive medication. Recent variations in geographic differences in hypertension prevalence in the United States are less well known. To assess state-level trends in self-reported hypertension and treatment among U.S. adults, CDC analyzed 2005-2009 data from the Behavioral Ris...
Source: MMWR Morb Mortal Wkl... - April 5, 2013 Category: Epidemiology Authors: Centers for Disease Control and Prevention (CDC) Tags: MMWR Morb Mortal Wkly Rep Source Type: research
An Effective Approach to High Blood Pressure Control A Science Advisory From the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention
Cardiovascular diseases, including heart disease, hypertension, and heart failure, along with stroke, continue to be leading causes of death in the United States (1,22). Hypertension currently affects nearly 78 million∗∗∗The estimate is based on the hypertension definition of blood pressure reading ≥140/90 mm Hg, current use of antihypertensive medications, or being told about having hypertension on 2 occasions by a healthcare provider. When the third component of the definition is excluded, the estimated number of prevalence cases among U.S. adults would be 67 million (3). adults in the United States and is al...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 24, 2014 Category: Cardiology Source Type: research
